CN113546100A - Application of sweet potato extract in preparation of antibacterial product - Google Patents

Application of sweet potato extract in preparation of antibacterial product Download PDF

Info

Publication number
CN113546100A
CN113546100A CN202110845730.1A CN202110845730A CN113546100A CN 113546100 A CN113546100 A CN 113546100A CN 202110845730 A CN202110845730 A CN 202110845730A CN 113546100 A CN113546100 A CN 113546100A
Authority
CN
China
Prior art keywords
extract
concentration
equal
sweet potato
whole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110845730.1A
Other languages
Chinese (zh)
Other versions
CN113546100B (en
Inventor
刘红梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningxia Milk Melon Biotechnology Co ltd
Original Assignee
Ningxia Milk Melon Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningxia Milk Melon Biotechnology Co ltd filed Critical Ningxia Milk Melon Biotechnology Co ltd
Priority to CN202110845730.1A priority Critical patent/CN113546100B/en
Publication of CN113546100A publication Critical patent/CN113546100A/en
Application granted granted Critical
Publication of CN113546100B publication Critical patent/CN113546100B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Birds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses an application of a sweet potato extract in preparation of an antibacterial product. Belongs to the field of plant chemistry. The invention finds that the sweet potato extract has the bacteriostatic effect and is particularly effective to staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, candida albicans, proteus, salmonella typhi, pseudomonas aeruginosa and escherichia coli. In addition, different extracts have different bacteriostatic objects and effects, and have great potential in the development and research of future antibacterial drugs.

Description

Application of sweet potato extract in preparation of antibacterial product
Technical Field
The invention relates to the technical field of phytochemistry, in particular to application of a sweet potato extract in preparation of an antibacterial product.
Background
At present, synthetic compounds are mainly used as antibacterial drugs at home and abroad, and although the compounds can effectively kill pathogenic microorganisms, the toxicity and the irritation of the compounds influence the health of human bodies to different degrees. In recent years, the development of resistant strains has become the most problematic problem for clinical treatment due to abuse of antibiotics. The development of novel antibiotics requires a long period, so that the development of traditional Chinese medicines or effective components with antibacterial activity from traditional Chinese medicines is very important.
The pachyrhizus (Cynanchulm thesides (Freyn) K.Schulm) is a perennial herb of the genus Anseris of the family Asclepiadaceae, is distributed in arid areas such as northeast, North China, inner Mongolia and the like, and has abundant resources. The Mongolian name is Temo-Hull, and the Mongolian name is Gekko Swinhonis, named as Gekko Swinhonis, and Nychnos. The whole herbs and fruits are used as Chinese medicine, and have the effects of tonifying lung qi, clearing heat, reducing pathogenic fire, promoting fluid production, quenching thirst, diminishing inflammation, relieving pain, dispelling pathogenic wind, promoting blood circulation, and relieving diarrhea. In recent years, studies on the sweet potatoes mainly focus on chemical components, tissue culture and artificial domestication, content measurement and quality standards, and the studies on practical products are less. The aim of deep utilization of resources is achieved by researching the antibacterial action of the sweet potatoes.
To date, the art has not found any antibacterial efficacy of sweet potato. Therefore, the invention firstly provides that the sweet potato extract has the antibacterial effect.
Staphylococcus aureus (also known as Staphylococcus aureus) is a common gram-positive bacterium and widely found in air, water, dust and human and animal excreta. It is a zoonosis pathogen, can cause various diseases of human and animals, including pseudomembranous enteritis, septicemia, sepsis and the like, and seriously threatens the life safety of human and animals.
Staphylococcus epidermidis (Staphylococcus epidermidis) is a type of bacterium that grows on the epidermis of an organism. Parasitizing on skin, vagina and other parts of a human body belongs to a normal flora type. Staphylococci are a group of gram-positive cocci, so called because they are often piled up in the form of strings. Most are nonpathogenic and few can cause disease. Staphylococci are the most common pyogenic cocci and are an important source of nosocomial cross-infections.
Klebsiella pneumoniae (gtreptococculspneummonias) it is responsible for the major pneumonia of human lobar pneumonia. 75% of adult Klebsiella pneumoniae and more than 50% of severe Klebsiella pneumoniae bacteremia are caused by Klebsiella pneumoniae types 1-8. Klebsiella pneumoniae types 6, 14, 19 and 23, often cause Klebsiella pneumoniae disease in children. 40-70% of normal human upper respiratory tract carries virulent klebsiella pneumoniae.
Candida Albicans (Candida Albicans), also known as Candida Albicans and Candida Albicans. Widely exists in the nature, also exists in normal human oral cavity, upper respiratory tract, intestinal tract and vagina, is a normal fungus parasitizing on the skin mucous membrane of a human body, and is also a clinically important conditional pathogenic bacterium.
Proteus (Streptococcus multans) is a gram-positive coccus, one of the largest proportion of Streptococcus in the natural flora of the oral cavity, and is one of the main components of dental plaque. Caries is a bacterial infectious disease occurring in the hard tissues of the teeth, with the highest incidence of oral disease. The proteus is the main pathogenic bacterium of caries, and the transmission mode of the proteus is various and mainly comprises maternal transmission, paternal transmission and other transverse transmission modes.
Salmonella typhi (Salmonella typhi) is the causative agent of typhoid disease, a serotype of Salmonella enterica. The infection route is a feces-oral route, and the infection power is very strong. The main symptom of the infected people is high fever which can reach 39-40 ℃; other symptoms include abdominal pain, severe diarrhea, headache, body color spot with roses, etc., which are often called cold and heat; bleeding or perforation of the bowel is its most serious complication.
Pseudomonas aeruginosa (Pseudomonas aeruginosa) belongs to the genus Pseudomonas, and is an aerobic gram-negative bacterium. Pseudomonas aeruginosa infections of the skin often occur in persistently moist lesions, especially around the umbilicus of infants, on burned surfaces, as well as in impregnated toe webs, the external auditory canal, and pinna.
Escherichia coli (Escherichia coli), also known as Escherichia coli, is a normal colonizing bacterium in the intestinal tract of animals, a small proportion of which causes disease under certain conditions. Serotypes of escherichia coli can cause gastrointestinal infections in humans and animals, mainly caused by infection with specific pilus antigens, pathogenic toxins, and the like, and can cause urinary tract infections, arthritis, meningitis, sepsis type infections, and the like, in addition to gastrointestinal infections.
Therefore, the full utilization of the antibacterial efficacy of the sweet potato extract is a problem that needs to be solved by those skilled in the art.
Disclosure of Invention
In view of the above, the invention provides an application of a sweet potato extract in preparing an antibacterial product.
The invention finds that the sweet potato extract has the bacteriostatic action, and specifically comprises staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, candida albicans, proteus, salmonella typhi, pseudomonas aeruginosa and escherichia coli. In addition, the sweet potato extract has no toxic or side effect and is safe.
In order to achieve the purpose, the invention adopts the following technical scheme:
the application of the sweet potato extract in preparing an antibacterial product comprises the following components: the whole grass water extract, the water part after the whole grass water extract is extracted, the n-butanol extraction part of the whole grass water extract, the dichloromethane extraction part of the whole grass water extract, the ethyl acetate extraction part of the whole grass water extract, the ethanol part after the whole grass water extract is precipitated by 90 percent ethanol, and the polysaccharide component in the whole grass or the petroleum ether extraction part of the whole grass water extract.
Preferably:
the sweet potato extract is a whole-grass water extract, and the concentration of active ingredients is more than or equal to 0.5012 g/ml;
when the pachyrhizus extract is the water part extracted from the whole-grass water extract, the concentration of the effective components is more than or equal to 0.2551 g/ml;
when the sweet potato extract is the n-butanol extraction part of the whole-grass water extract, the concentration of the effective components is more than or equal to 0.1300 g/ml;
when the extract of the pachyrhizus is the extracted part of the dichloromethane, the concentration of the effective components is more than or equal to 0.0028 g/ml;
when the sweet potato extract is an ethyl acetate extraction part, the concentration of effective components is more than or equal to 0.0717 g/ml;
when the sweet potato extract is ethanol part of the whole grass water extract after being precipitated by 90% ethanol, the concentration of the effective components is more than or equal to 0.1266 g/ml;
when the sweet potato extract is a polysaccharide component in the whole grass, the concentration of the effective component is more than or equal to 0.5016 g/ml;
when the radix Pachyrhizi Erosi extract is the petroleum ether extract of the whole plant water extract, the concentration of effective components is not less than 0.0100 g/ml.
Preferably:
when the sweet potato extract is a whole grass water extract:
0.1002g/ml, when the concentration of the effective components is more than or equal to 0.5012g/ml, the bacteriostatic object is pseudomonas aeruginosa;
when the concentration of the effective components is more than or equal to 0.1002g/ml, the antibacterial objects are staphylococcus aureus, salmonella typhi, candida albicans, pseudomonas aeruginosa and escherichia coli;
when the sweet potato extract is the water part extracted by the whole-grass water extract:
1.0205g/ml, when the concentration of the effective components is more than or equal to 0.2551g/ml, the bacteriostatic object is pseudomonas aeruginosa;
when the concentration of the effective components is more than or equal to 1.0205g/ml, the antibacterial objects are Klebsiella pneumoniae, Proteus proteus, Salmonella typhi, Pseudomonas aeruginosa, Candida albicans and Escherichia coli;
when the pachyrhizus extract is a n-butyl alcohol extraction part of a whole-grass water extract:
0.2600g/ml, when the concentration of the effective component is more than or equal to 0.1300g/ml, the bacteriostatic object is staphylococcus aureus;
0.5200g/ml, when the concentration of the effective components is more than or equal to 0.2600g/ml, the bacteriostatic objects are staphylococcus aureus, staphylococcus epidermidis, proteus, salmonella typhi and escherichia coli;
when the concentration of the effective components is more than or equal to 0.5200g/ml, the antibacterial objects are staphylococcus aureus, staphylococcus epidermidis, proteus, salmonella typhi, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa;
when the sweet potato extract is a dichloromethane extracted part:
when the concentration of 0.0112g/ml is more than or equal to 0.0028g/ml, the antibacterial object is staphylococcus epidermidis;
when the concentration of 0.0225g/ml of the effective components is more than or equal to 0.0112g/ml, the antibacterial objects are staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, salmonella typhi and escherichia coli;
when the concentration of the effective components is more than or equal to 0.0225g/ml, the antibacterial objects are staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, proteus, salmonella typhi, pseudomonas aeruginosa and escherichia coli;
when the sweet potato extract is an ethyl acetate extraction part:
0.1434g/ml, when the concentration of the effective component is more than or equal to 0.0717g/ml, the bacteriostatic objects are staphylococcus aureus, staphylococcus epidermidis and salmonella typhi;
0.2869g/ml, when the concentration of the effective components is more than or equal to 0.1434g/ml, the bacteriostatic objects are staphylococcus aureus, staphylococcus epidermidis, salmonella typhi, proteus, pseudomonas aeruginosa and escherichia coli;
when the concentration of the effective components is more than or equal to 0.2869g/ml, the antibacterial objects are staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, candida albicans, proteus, salmonella typhi, pseudomonas aeruginosa and escherichia coli;
when the sweet potato extract is the ethanol part after the whole-grass water extract is precipitated by 90 percent ethanol:
0.5066g/ml, when the concentration of the effective components is more than or equal to 0.1266g/ml, the bacteriostatic object is pseudomonas aeruginosa;
1.0133g/ml, when the concentration of the effective components is more than or equal to 0.5066g/ml, the bacteriostatic objects are pseudomonas aeruginosa and escherichia coli;
when the concentration of the effective components is more than or equal to 1.0133g/ml, the bacteriostatic objects are pseudomonas aeruginosa, escherichia coli and candida albicans;
when the pachyrhizus extract is a polysaccharide component in the whole grass, the bacteriostatic object is pseudomonas aeruginosa;
when the sweet potato extract is the part extracted from the whole-grass water extract by petroleum ether, the bacteriostatic objects are staphylococcus aureus and staphylococcus epidermidis.
Preferably: the antibacterial product is a cosmetic.
The extract of sweet potato can be prepared by conventional extraction methods, for example, by solvent extraction. The extraction solvent used in the extraction process comprises distilled water, dichloromethane, ethyl acetate and n-butanol. Except distilled water, other reagents were analytically pure.
According to the technical scheme, compared with the prior art, the invention discloses and provides the application of the sweet potato extract in preparing the antibacterial product. The bacteriostatic action of the extract of sweet potato has a number of advantages over chemically synthesized compounds compared to the prior art. Firstly, the sweet potato extract has the advantages of definite curative effect, small toxic and side effect and the like, and better meets the requirements of nature, safety and environmental protection. In consumer groups, the Chinese herbal medicine extract as the bacteriostatic agent has wide application prospect and huge market value. Secondly, the sweet potato extract extracted from Chinese herbal medicines serving as raw materials has the advantages of difficult generation of drug resistance, capability of reversing bacterial drug resistance and the like due to the characteristics of multiple components and multiple targets, and has great development potential in the aspect of treatment of bacterial infection diseases.
In addition, the research on the pachyrhizus in the prior art is mainly focused on the clinical application and compatibility. The medicinal value of the sweet potato is mainly reflected in the effects of treating diarrhea and resisting aging at present. However, the extract of the sweet potato has bacteriostatic effect, and is particularly effective to staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, candida albicans, proteus, salmonella typhi, pseudomonas aeruginosa and escherichia coli. In addition, different extracts have different bacteriostatic objects and effects, and have great potential in the development and research of future antibacterial drugs.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.
FIG. 1 is a drawing showing the specimen No. 1 provided by the present invention.
FIG. 2 is a drawing showing an observation of the specimen plate No. 1 according to the present invention.
FIG. 3 is a drawing of specimen No. 8 provided by the present invention.
FIG. 4 is a drawing showing an observation of the specimen No. 8 plate according to the present invention.
FIG. 5 is a specimen diagram No. 9 provided by the present invention.
FIG. 6 is a drawing showing an observation of the specimen No. 9 plate according to the present invention.
FIG. 7 is a drawing of specimen No. 10 provided by the present invention.
FIG. 8 is a drawing showing an observation of a No. 10 specimen plate according to the present invention.
FIG. 9 is a drawing of specimen No. 11 according to the present invention.
FIG. 10 is a drawing showing an observation of the specimen plate No. 11 according to the present invention.
FIG. 11 is a drawing of specimen No. 12 according to the present invention.
FIG. 12 is a drawing showing an observation of a No. 12 specimen plate according to the present invention.
FIG. 13 is a drawing of specimen No. 13 according to the present invention.
FIG. 14 is a drawing showing an observation of the No. 13 specimen plate according to the present invention.
FIG. 15 is a drawing of specimen No. 14 according to the present invention.
FIG. 16 is a drawing showing an observation of a No. 14 specimen plate according to the present invention.
FIG. 17 is a drawing of specimen No. 15 according to the present invention.
FIG. 18 is a drawing showing an observation of a specimen No. 15 plate according to the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The embodiment of the invention discloses application of a sweet potato extract in preparation of an antibacterial product.
Example 1
Preparation of sweet potato extract
Weighing 200g of sweet potato medicinal material, placing the sweet potato medicinal material into a round-bottom flask, adding 2000mL of distilled water, fully stirring, placing the mixture at room temperature, heating and refluxing for extraction for 1h (the extraction temperature is 100 ℃), filtering the mixture by using 8 layers of gauze, combining the filtrate repeatedly for three times, then concentrating the filtrate under reduced pressure (the water bath temperature is 60 ℃, and the vacuum degree is 0.08MPa.), concentrating the filtrate to be viscous, and pouring the viscous liquid out of an evaporation dish. Drying in an electric heating constant temperature air-blast drying oven (DHG-9140A) (drying condition temperature 60 deg.C), and weighing extract amount 40g (water content less than 5%).
Weighing 30g of extract, putting the extract into a beaker, adding 100mL of distilled water, fully stirring at room temperature until the extract is dissolved, then pouring the extract into a 250mL separating funnel, adding 100mL of dichloromethane, fully shaking and standing for 24h for separating liquid, and discharging the lower layer solution from a lower port, (wherein the upper layer solution is a water layer, and the lower layer solution is a dichloromethane layer). The dichloromethane layer was placed in a 500mL beaker, 100mL of dichloromethane was added to the separatory funnel, the mixture was shaken well and left for 24 hours to separate the solution, and the lower solution was discharged from the lower port into the 500mL beaker. This was repeated until the extract was colorless. Then, the ethyl acetate and the n-butanol are used for replacing dichloromethane, and the operation is repeated. (Ethyl acetate, n-butanol in the upper layer; poured out from the upper layer). Finally the aqueous layer was decanted from the lower layer. Obtaining extract liquid of different parts. Then the extract is concentrated under reduced pressure (the reduced pressure condition is that the temperature of the water bath is 60 ℃, the vacuum degree is 0.08 MPa), and the extract is concentrated to be viscous and poured out to an evaporating dish. Drying in an electric heating constant temperature air-blast drying oven (DHG-9140A) (drying condition temperature 60 deg.C) and weighing extract amount (water content less than 5%).
Weighing 100g of whole sweet potato, placing into a round-bottom flask, adding 1000mL of distilled water, fully stirring, heating and refluxing at room temperature for 1h (the extraction temperature is 100 ℃), filtering with 8 layers of gauze, repeating for three times, combining the filtrates, concentrating the filtrate under reduced pressure (the water bath temperature is 60 ℃, and the vacuum degree is 0.08MPa.) to about the residual 200mL, adding about 1067mL of 95% ethanol to about 80% ethanol, and standing overnight. And pouring out the supernatant, concentrating to be viscous, and pouring out to an evaporation dish. Drying in an electric heating constant temperature blast drying oven (DHG-9140A) (drying condition temperature 60 deg.C) and weighing extract amount (water content less than 5%), obtaining alcohol part, centrifuging lower layer precipitate at 3000r/min for 10min, and removing protein from the obtained precipitate by sevage method to obtain crude polysaccharide.
Example 2
Anti-bacteria function of sweet potato extract
1. Standard strains (all commercially available): staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Candida albicans, Proteus, Salmonella typhi, Pseudomonas aeruginosa, and Escherichia coli. Single and double feed nutrient broths were purchased from hangzhou day and microbial agents limited.
2. The method comprises the following operation steps:
sample preparation: taking the obtained extract, and preparing a sample solution with the concentration of about 2 g/mL.
The dilution ratios of the test samples are given in Table 1 below
TABLE 1
Figure BDA0003180704420000081
3. Preparing a test reagent micro-dilution disc: a 96-well sterile cell culture plate (see table 2) was taken and labeled. 100ul of the diluted test drug samples in the test tubes of 12 multiplied by 100mm are sucked by a sample injector and placed in corresponding holes of a sterile cell culture plate; and synchronously testing the activity of the test bacteria.
TABLE 2
Figure BDA0003180704420000082
Figure BDA0003180704420000091
Figure BDA0003180704420000101
4. Preparation of inoculum solution and inoculation
Selecting several colonies from agar plate cultured for 18-24 hr, directly preparing into bacterial suspension in sterile normal saline, and calibrating turbidity of bacterial suspension to 0.5 McLeod unit (containing 1 × 108CFul/ml), and then diluted 1:20 to make its bacteria content 5X 106CFul/ml, adding 0.01ml (10ul)5 x 10 to 0.1ml of sample per well of the test drug microdilution plate6CFul/ml. The bacterial suspension has a final test bacterial liquid concentration of 5 x 104CFul/well.
5. And (3) incubation: and placing the inoculated micro-dilution plate in an incubator at the temperature of 35 +/-2 ℃ for incubation for 16-20 h. To keep the incubation temperature the same for all cultures, no more than 4 microdilution plates should be placed on top of each other. To prevent drying, the dilution tray should be sealed with plastic bags.
6. Interpretation of MIC results
Because the color of the medicine is darker and the observation of the Minimum Inhibitory Concentration (MIC) is influenced, a standard inoculating loop liquid culture is taken by an inoculating loop after the culture and is subjected to intensive streak transformation on an MH agar plate, after the culture is continued for 24 hours, the observation of the existence of bacterial growth is carried out, and the minimum medicine concentration without bacterial growth or with the number of bacteria less than 5 is the Minimum Inhibitory Concentration (MIC) of the medicine.
7. Results of the experiment
The No. 1 specimen is a whole grass water extract, the No. 8 specimen is a water part extracted by a whole grass water extract, the No. 9 specimen is a whole grass water extract n-butyl alcohol extraction part, the No. 10 specimen is a whole grass water extract dichloromethane extraction part, the No. 11 specimen is a whole grass water extract ethyl acetate extraction part, the No. 12 specimen is a whole grass water extract ethanol part precipitated by 90% ethanol, the No. 13 specimen is a whole grass medium polysaccharide component, the No. 14 specimen is a whole grass water extract petroleum ether extraction part, and the No. 15 specimen is a whole grass medium protein component.
Specimen No. 1:
Figure BDA0003180704420000111
specimen No. 8:
Figure BDA0003180704420000112
Figure BDA0003180704420000121
specimen No. 9:
Figure BDA0003180704420000122
note: the criterion was less than + (6).
Sample No. 10:
Figure BDA0003180704420000123
Figure BDA0003180704420000131
sample No. 11:
Figure BDA0003180704420000132
sample No. 12:
Figure BDA0003180704420000133
Figure BDA0003180704420000141
sample No. 13:
Figure BDA0003180704420000142
sample No. 14:
Figure BDA0003180704420000151
sample No. 15:
Figure BDA0003180704420000152
Figure BDA0003180704420000161
the embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims (4)

1. The application of the sweet potato extract in preparing an antibacterial product is characterized in that the sweet potato extract comprises: the whole grass water extract, the water part after the whole grass water extract is extracted, the n-butanol extraction part of the whole grass water extract, the dichloromethane extraction part of the whole grass water extract, the ethyl acetate extraction part of the whole grass water extract, the ethanol part after the whole grass water extract is precipitated by 90 percent ethanol, and the polysaccharide component in the whole grass or the petroleum ether extraction part of the whole grass water extract.
2. The use of a sweet potato extract as claimed in claim 1 for the preparation of an antibacterial product, wherein:
the sweet potato extract is a whole-grass water extract, and the concentration of active ingredients is more than or equal to 0.5012 g/ml;
when the pachyrhizus extract is a water part extracted from the whole-grass water extract, the concentration of active ingredients is more than or equal to 0.2551 g/ml;
when the sweet potato extract is the n-butanol extraction part of the whole-grass water extract, the concentration of the effective components is more than or equal to 0.1300 g/ml;
when the sweet potato extract is a dichloromethane extraction part, the concentration of effective components is more than or equal to 0.0028 g/ml;
when the sweet potato extract is an ethyl acetate extraction part, the concentration of effective components is more than or equal to 0.0717 g/ml;
when the sweet potato extract is ethanol part after the whole-grass water extract is precipitated by 90% ethanol, the concentration of the effective component is more than or equal to 0.1266 g/ml;
when the sweet potato extract is a polysaccharide component in the whole grass, the concentration of the effective component is more than or equal to 0.5016 g/ml;
when the pachyrhizus extract is part of the whole-grass aqueous extract extracted by petroleum ether, the concentration of the effective components is more than or equal to 0.0100 g/ml.
3. The use of a sweet potato extract as claimed in claim 2 for the preparation of an antibacterial product, wherein:
when the sweet potato extract is a whole grass water extract:
0.1002g/ml, when the concentration of the effective components is more than or equal to 0.5012g/ml, the bacteriostatic object is pseudomonas aeruginosa;
when the concentration of the effective components is more than or equal to 0.1002g/ml, the antibacterial objects are staphylococcus aureus, salmonella typhi, candida albicans, pseudomonas aeruginosa and escherichia coli;
when the pachyrhizus extract is a water part extracted by the whole-grass water extract:
1.0205g/ml, when the concentration of the effective components is more than or equal to 0.2551g/ml, the bacteriostatic object is pseudomonas aeruginosa;
when the concentration of the effective components is more than or equal to 1.0205g/ml, the antibacterial objects are Klebsiella pneumoniae, Proteus proteus, Salmonella typhi, Pseudomonas aeruginosa, Candida albicans and Escherichia coli;
when the sweet potato extract is the n-butanol extraction part of the whole-grass water extract:
0.2600g/ml, when the concentration of the effective component is more than or equal to 0.1300g/ml, the bacteriostatic object is staphylococcus aureus;
0.5200g/ml, when the concentration of the effective components is more than or equal to 0.2600g/ml, the bacteriostatic objects are staphylococcus aureus, staphylococcus epidermidis, proteus, salmonella typhi and escherichia coli;
when the concentration of the effective components is more than or equal to 0.5200g/ml, the antibacterial objects are staphylococcus aureus, staphylococcus epidermidis, proteus, salmonella typhi, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa;
when the sweet potato extract is a dichloromethane extraction part:
when the concentration of 0.0112g/ml is more than or equal to 0.0028g/ml, the antibacterial object is staphylococcus epidermidis;
when the concentration of 0.0225g/ml of the effective components is more than or equal to 0.0112g/ml, the antibacterial objects are staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, salmonella typhi and escherichia coli;
when the concentration of the effective components is more than or equal to 0.0225g/ml, the antibacterial objects are staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, proteus, salmonella typhi, pseudomonas aeruginosa and escherichia coli;
when the sweet potato extract is an ethyl acetate extraction part:
0.1434g/ml, when the concentration of the effective component is more than or equal to 0.0717g/ml, the bacteriostatic objects are staphylococcus aureus, staphylococcus epidermidis and salmonella typhi;
0.2869g/ml, when the concentration of the effective components is more than or equal to 0.1434g/ml, the bacteriostatic objects are staphylococcus aureus, staphylococcus epidermidis, salmonella typhi, proteus, pseudomonas aeruginosa and escherichia coli;
when the concentration of the effective components is more than or equal to 0.2869g/ml, the antibacterial objects are staphylococcus aureus, staphylococcus epidermidis, klebsiella pneumoniae, candida albicans, proteus, salmonella typhi, pseudomonas aeruginosa and escherichia coli;
when the sweet potato extract is the ethanol part after the whole-grass water extract is precipitated by 90% ethanol:
0.5066g/ml, when the concentration of the effective components is more than or equal to 0.1266g/ml, the bacteriostatic object is pseudomonas aeruginosa;
1.0133g/ml, when the concentration of the effective components is more than or equal to 0.5066g/ml, the bacteriostatic objects are pseudomonas aeruginosa and escherichia coli;
when the concentration of the effective components is more than or equal to 1.0133g/ml, the bacteriostatic objects are pseudomonas aeruginosa, escherichia coli and candida albicans;
when the pachyrhizus extract is a polysaccharide component in the whole grass, the bacteriostatic object is pseudomonas aeruginosa;
when the sweet potato extract is the part extracted from the whole-grass water extract by petroleum ether, the bacteriostatic objects are staphylococcus aureus and staphylococcus epidermidis.
4. The use of a sweet potato extract as claimed in any one of claims 1 to 3 in the preparation of an antibacterial product, wherein: the antibacterial product is a cosmetic.
CN202110845730.1A 2021-07-26 2021-07-26 Application of pachyrhizus extract in preparation of antibacterial product Active CN113546100B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110845730.1A CN113546100B (en) 2021-07-26 2021-07-26 Application of pachyrhizus extract in preparation of antibacterial product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110845730.1A CN113546100B (en) 2021-07-26 2021-07-26 Application of pachyrhizus extract in preparation of antibacterial product

Publications (2)

Publication Number Publication Date
CN113546100A true CN113546100A (en) 2021-10-26
CN113546100B CN113546100B (en) 2022-07-12

Family

ID=78132833

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110845730.1A Active CN113546100B (en) 2021-07-26 2021-07-26 Application of pachyrhizus extract in preparation of antibacterial product

Country Status (1)

Country Link
CN (1) CN113546100B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104295A1 (en) * 2005-08-12 2009-04-23 Kenji Kohno Agent for Hair Growth
CN103877298A (en) * 2014-04-20 2014-06-25 王雪雪 Chinese medicament liquid medicine special for disinfection before operation and preparation method thereof
CN105309503A (en) * 2015-11-18 2016-02-10 无锡市稼宝药业有限公司 Botanical fungicide for anthracnose

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104295A1 (en) * 2005-08-12 2009-04-23 Kenji Kohno Agent for Hair Growth
CN103877298A (en) * 2014-04-20 2014-06-25 王雪雪 Chinese medicament liquid medicine special for disinfection before operation and preparation method thereof
CN105309503A (en) * 2015-11-18 2016-02-10 无锡市稼宝药业有限公司 Botanical fungicide for anthracnose

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PEI LINGPENG ET AL: "Effect of water extracts from Cynanchum thesioides (Freyn) K. Schum. on visceral hypersensitivity and gut microbiota profile in maternally separated rats", 《JOURNAL OF ETHNOPHARMACOLOGY》 *
唐铭琬: "食药两用植物地梢瓜的研究进展及应用探讨", 《食品安全质量检测学报》 *
李睿等: "地梢瓜叶中总黄酮的提取及含量测定", 《内蒙古民族大学学报(自然科学版)》 *

Also Published As

Publication number Publication date
CN113546100B (en) 2022-07-12

Similar Documents

Publication Publication Date Title
JP6713065B2 (en) Probiotic composition, skin care essence and mask, and method for producing the same
CN101812414B (en) Lactobacillus plantarum and bacteriocins produced by lactobacillus plantarum and capable of inhibiting Gram negative bacteria
CN108048347A (en) Lactobacillus rhamnosus, lactobacillus rhamnosus preparation and application thereof
CN111991429B (en) Application of lactobacillus reuteri in preparation of products for resisting oral bacterial infection
CN103409334B (en) Inhibit the Bacillus acidi lactici and application thereof of vaginitis pathogen
CN107828665B (en) Separation and purification method of arundina graminifolia endophytic fungi and application thereof
WO2013011679A1 (en) Bactericidal agent and method for producing same
CN103275893A (en) Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants
CN103911305B (en) Lactobacillus crispatus bacterial strain and uses thereof
WO2017067089A1 (en) Neovison vison klebsiella peneumoniae
CN115813971A (en) Radix astragali decoction pieces for treating acute otitis media and preparation method thereof
CN108542954A (en) A kind of Traditional Chinese medicine gel composition of inhibitory anti-virus
CN111568919A (en) A preparation containing chitosan oligosaccharide for resisting helicobacter pylori
CN109864943A (en) A kind of preparation method and application of bletilla striata polyphenol
CN111419829B (en) Application of honokiol in inhibiting streptococcus suis or biofilm thereof
CN103911307B (en) Lactobacillus crispatus bacterial strain and uses thereof
CN113546100B (en) Application of pachyrhizus extract in preparation of antibacterial product
CN105456306B (en) Rattan lycopod extract is preparing the application in antibacterial anti-inflammatory natural drug
CN109125399A (en) The antibacterial action of stephania tetrandra extract
CN107913397A (en) A kind of Tiny ecosystem gynaecologic washing lotion and preparation method thereof
CN103585277A (en) Application of clove leaf extractives in inhibition of streptococcus suis and intervention and elimination of streptococcus suis biofilm
CN110898123A (en) Traditional Chinese medicine composition for inhibiting growth of pathogenic microorganisms of animal vaginitis and preparation method and application thereof
TWI381858B (en) Vaginal cleaner and manufacture method thereof
JP2008526958A (en) Silver ionized plant extract and use thereof
CN105726390B (en) A kind of toothpaste for preventing gingivitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant